Cargando…
Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma
BACKGROUND: This study aimed to investigate the expression profile of TFE3 in renal cell carcinoma (RCC) and the clinicopathological features as well as prognosis of TFE3-positive RCC. METHODS: Tissue sections from 796 patients with RCC were collected for immunohistochemical staining of TFE3. Molecu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582134/ https://www.ncbi.nlm.nih.gov/pubmed/36276115 http://dx.doi.org/10.3389/fonc.2022.1017425 |
_version_ | 1784812767283249152 |
---|---|
author | Dong, Xiang Chen, Yuxin Pan, Jun Ma, Wenliang Zhou, Peng Chen, Ming Guo, Hongqian Gan, Weidong |
author_facet | Dong, Xiang Chen, Yuxin Pan, Jun Ma, Wenliang Zhou, Peng Chen, Ming Guo, Hongqian Gan, Weidong |
author_sort | Dong, Xiang |
collection | PubMed |
description | BACKGROUND: This study aimed to investigate the expression profile of TFE3 in renal cell carcinoma (RCC) and the clinicopathological features as well as prognosis of TFE3-positive RCC. METHODS: Tissue sections from 796 patients with RCC were collected for immunohistochemical staining of TFE3. Molecular TFE3 rearrangement tests were also carried out on the TFE3-positive RCCs using fluorescence in situ hybridization and RNA-sequencing assays. Both clinicopathological features and follow-up information were collected for further analysis. RESULTS: The present study showed that 91 patients with RCC (91/796, 11.4%) were TFE3 positive expression but only 31 (31/91, 34.1%) of the patients were diagnosed with Xp11.2 translocation RCC. Further, it was found that the patients with TFE3-positive RCCs were more likely to develop lymph node and distant metastasis at diagnosis as well as presented a significantly higher WHO/ISUP nuclear grade and AJCC stage as compared with patients with TFE3-negative RCCs (p<0.01). Results of univariate and multivariate analyses showed that TFE3 positive expression was an independent prognostic factor associated with poor progression-free survival. Further, the findings of survival analysis showed that patients with positive TFE3 expression showed a shorter progression-free survival as compared with the patients with negative expression of TFE3 (p<0.001). In addition, results of the survival analysis found that there was no significant difference in progression-free survival between the Xp11.2 translocation RCC and TFE3-positive non-Xp11.2 translocation RCC groups (p=0.9607). CONCLUSION: This study found that nuclear TFE3 expression is not specific to the Xp11.2 translocation RCC. Moreover, the positive TFE3 expression is associated with tumor progression and poor prognosis in patients with RCC irrespective of the presence of TFE3 translocation. |
format | Online Article Text |
id | pubmed-9582134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95821342022-10-21 Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma Dong, Xiang Chen, Yuxin Pan, Jun Ma, Wenliang Zhou, Peng Chen, Ming Guo, Hongqian Gan, Weidong Front Oncol Oncology BACKGROUND: This study aimed to investigate the expression profile of TFE3 in renal cell carcinoma (RCC) and the clinicopathological features as well as prognosis of TFE3-positive RCC. METHODS: Tissue sections from 796 patients with RCC were collected for immunohistochemical staining of TFE3. Molecular TFE3 rearrangement tests were also carried out on the TFE3-positive RCCs using fluorescence in situ hybridization and RNA-sequencing assays. Both clinicopathological features and follow-up information were collected for further analysis. RESULTS: The present study showed that 91 patients with RCC (91/796, 11.4%) were TFE3 positive expression but only 31 (31/91, 34.1%) of the patients were diagnosed with Xp11.2 translocation RCC. Further, it was found that the patients with TFE3-positive RCCs were more likely to develop lymph node and distant metastasis at diagnosis as well as presented a significantly higher WHO/ISUP nuclear grade and AJCC stage as compared with patients with TFE3-negative RCCs (p<0.01). Results of univariate and multivariate analyses showed that TFE3 positive expression was an independent prognostic factor associated with poor progression-free survival. Further, the findings of survival analysis showed that patients with positive TFE3 expression showed a shorter progression-free survival as compared with the patients with negative expression of TFE3 (p<0.001). In addition, results of the survival analysis found that there was no significant difference in progression-free survival between the Xp11.2 translocation RCC and TFE3-positive non-Xp11.2 translocation RCC groups (p=0.9607). CONCLUSION: This study found that nuclear TFE3 expression is not specific to the Xp11.2 translocation RCC. Moreover, the positive TFE3 expression is associated with tumor progression and poor prognosis in patients with RCC irrespective of the presence of TFE3 translocation. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582134/ /pubmed/36276115 http://dx.doi.org/10.3389/fonc.2022.1017425 Text en Copyright © 2022 Dong, Chen, Pan, Ma, Zhou, Chen, Guo and Gan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Dong, Xiang Chen, Yuxin Pan, Jun Ma, Wenliang Zhou, Peng Chen, Ming Guo, Hongqian Gan, Weidong Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma |
title | Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma |
title_full | Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma |
title_fullStr | Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma |
title_full_unstemmed | Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma |
title_short | Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma |
title_sort | clinicopathological features and prognosis of tfe3-positive renal cell carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582134/ https://www.ncbi.nlm.nih.gov/pubmed/36276115 http://dx.doi.org/10.3389/fonc.2022.1017425 |
work_keys_str_mv | AT dongxiang clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma AT chenyuxin clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma AT panjun clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma AT mawenliang clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma AT zhoupeng clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma AT chenming clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma AT guohongqian clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma AT ganweidong clinicopathologicalfeaturesandprognosisoftfe3positiverenalcellcarcinoma |